RT Journal Article
SR Electronic
T1 South African Population Immunity and Severe Covid-19 with Omicron Variant
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.20.21268096
DO 10.1101/2021.12.20.21268096
A1 Madhi, Shabir A.
A1 Kwatra, Gaurav
A1 Myers, Jonathan E.
A1 Jassat, Waasila
A1 Dhar, Nisha
A1 Mukendi, Christian K.
A1 Nana, Amit J.
A1 Blumberg, Lucille
A1 Welch, Richard
A1 Ngorima-Mabhena, Nicoletta
A1 Mutevedzi, Portia C.
YR 2021
UL http://medrxiv.org/content/early/2021/12/21/2021.12.20.21268096.abstract
AB Background We conducted a seroepidemiological survey from October 22 to December 9, 2021, in Gauteng Province, South Africa, to determine SARS-CoV-2 immunoglobulin G (IgG) seroprevalence primarily prior to the fourth wave of coronavirus disease 2019 (Covid-19), in which the B.1.1.529 (Omicron) variant is dominant. We evaluated epidemiological trends in case rates and rates of severe disease through to December 15, 2021, in Gauteng.Methods We contacted households from a previous seroepidemiological survey conducted from November 2020 to January 2021, plus an additional 10% of households using the same sampling framework. Dry blood spot samples were tested for anti-spike and anti-nucleocapsid protein IgG using quantitative assays on the Luminex platform. Daily case and death data, weekly excess deaths, and weekly hospital admissions were plotted over time.Results Samples were obtained from 7010 individuals, of whom 1319 (18.8%) had received a Covid-19 vaccine. Overall seroprevalence ranged from 56.2% (95% confidence interval [CI], 52.6 to 59.7) in children aged <12 years to 79.7% (95% CI, 77.6 to 81.5) in individuals aged >50 years. Seropositivity was 6.22-fold more likely in vaccinated (93.1%) vs unvaccinated (68.4%) individuals. Epidemiological data showed SARS-CoV-2 infection rates increased more rapidly than in previous waves but have now plateaued. Rates of hospitalizations and excess deaths did not increase proportionately, remaining relatively low.Conclusions We demonstrate widespread underlying SARS-CoV-2 seropositivity in Gauteng Province prior to the current Omicron-dominant wave, with epidemiological data showing an uncoupling of hospitalization and death rates from infection rate during Omicron circulation.Competing Interest StatementDr. Madhi reports grants from the Bill & Melinda Gates Foundation during the conduct of the study, grants and personal fees from the Bill & Melinda Gates Foundation, grants from the South African Medical Research Council, grants from Novavax, grants from Pfizer, grants from Minervax, and grants from the European & Developing Countries Clinical Trials Partnership, outside the submitted work. Dr. Kwatra, Dr. Dhar, Mr. Mukendi, Mr. Nana, Dr. Ngorima-Mabhena, and Dr. Mutevedzi report grants from the Bill & Melinda Gates Foundation during the conduct of the study. Mr. Welch shareholdings in Adcock Ingram Holdings Ltd, Aspen Pharmacare Holdings Ltd, Dischem Pharmacies Ltd, Discovery Ltd, and Netcare Ltd, outside the submitted work. Dr. Myers, Dr. Jassat, and Dr. Blumberg have nothing to disclose.Funding StatementFunding support for this survey was provided by the Bill & Melinda Gates Foundation (grant number: INV-023514).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Human Research Ethics Committee at the University of the Witewatersrand granted a waiver for ethics approval of the survey, which was being done at the behest of Guateng Department of Health as part of public health surveillance. Neverthless, informed consent was obtained from all indviduals, who were able to decline participation.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available at www.wits-vida.org; requests for data sharing should be directed to Professor Shabir A. Madhi, email: Shabir.Madhi{at}wits.ac.za